Miach Orthopaedics and the Biology of ACL Reconstruction

article image

Using tissue engineering technology, Miach Orthopaedics is pioneering a novel approach to ACL reconstruction that mirrors a larger trend in medical device development away from mechanical approaches toward biological ones.

In the late 1980s, while a graduate student in material science and engineering at Stanford, Martha Murray, MD, now an orthopedic surgeon practicing in Boston, was at a party where she met a friend, newly on crutches, who had torn his anterior cruciate ligament (ACL) skiing. ACL surgery back then and even now was a procedure involving the removal of the torn tissue, harvesting the patient’s tendons, running them through tunnels drilled in the bone and anchoring them, followed by six months of rehab, with the risk that the patient might not regain full use of his or her knee again. As Murray’s friend described the surgery he had undergone, her first thought was, “That can’t be the best solution.”

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: